Literature DB >> 1590690

The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

J A Coates1, N Cammack, H J Jenkinson, I M Mutton, B A Pearson, R Storer, J M Cameron, C R Penn.   

Abstract

Racemic 2'-deoxy-3'-thiacytidine (BCH 189) is a dideoxycytidine analog having a sulfur atom in place of the 3' carbon. The enantiomers of BCH 189 have been resolved and found to be equipotent in antiviral activity against human immunodeficiency virus types 1 and 2. However, the (-)-enantiomer (3TC) is considerably less cytotoxic than the (+)-enantiomer.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1590690      PMCID： PMC189255          DOI： 10.1128/AAC.36.1.202

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus.

Authors:  R Pauwels; E De Clercq; J Desmyter; J Balzarini; P Goubau; P Herdewijn; H Vanderhaeghe; M Vandeputte
Journal:  J Virol Methods       Date:  1987-06       Impact factor: 2.014

2.  Resolution of racemic carbocyclic analogues of purine nucleosides through the action of adenosine deaminase. Antiviral activity of the carbocyclic 2'-deoxyguanosine enantiomers.

Authors:  J A Secrist; J A Montgomery; Y F Shealy; C A O'Dell; S J Clayton
Journal:  J Med Chem       Date:  1987-04       Impact factor: 7.446

3.  Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds.

Authors:  R Pauwels; J Balzarini; M Baba; R Snoeck; D Schols; P Herdewijn; J Desmyter; E De Clercq
Journal:  J Virol Methods       Date:  1988-08       Impact factor: 2.014

4.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer.

Authors:  R Vince; J Brownell
Journal:  Biochem Biophys Res Commun       Date:  1990-05-16       Impact factor: 3.575

6.  Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog.

Authors:  H Soudeyns; X I Yao; Q Gao; B Belleau; J L Kraus; N Nguyen-Ba; B Spira; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  D D Richman; M A Fischl; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; M S Hirsch
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

10.  Phase I studies of 2',3'-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT).

Authors:  R Yarchoan; C F Perno; R V Thomas; R W Klecker; J P Allain; R J Wills; N McAtee; M A Fischl; R Dubinsky; M C McNeely
Journal:  Lancet       Date:  1988-01-16       Impact factor: 79.321
View more
  63 in total

1.  Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes.

Authors:  R F Schinazi; C K Chu; A Peck; A McMillan; R Mathis; D Cannon; L S Jeong; J W Beach; W B Choi; S Yeola
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  L-ATP is recognized by some cellular and viral enzymes: does chance drive enzymic enantioselectivity?

Authors:  A Verri; A Montecucco; G Gosselin; V Boudou; J L Imbach; S Spadari; F Focher
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

3.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 4.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

Authors:  M Tisdale; S D Kemp; N R Parry; B A Larder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

Review 7.  Clinical pharmacokinetics of lamivudine.

Authors:  M A Johnson; K H Moore; G J Yuen; A Bye; G E Pakes
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

8.  Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Authors:  Ryuta Sakuma; Toshie Sakuma; Seiga Ohmine; Robert H Silverman; Yasuhiro Ikeda
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

9.  Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.

Authors:  C Solas; Y F Li; M Y Xie; J P Sommadossi; X J Zhou
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(--)-beta-L-2', 3'-dideoxy-3'-thiacytidine] in vitro.

Authors:  K P Fischer; D L Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.